Hong Kong consensus defines when to consider local ablative therapy in oncogene-driven NSCLC
The Hong Kong SBRT Study Group recommends risk-adapted local therapy for selected oncogene-driven NSCLC, including oligoresidual, oligoprogressive, and intracranial disease.